Welcome. Our next presenter is from INVO Fertility. Let's give him a warm welcome. Thank you. Hopefully, you guys can hear me okay. Great. We appreciate everyone being here today to give us an opportunity to tell you a little bit about INVO Fertility. As our name describes, we're in the fertility industry. Our focus involves really just helping people realize their dream of having a child. Some of you may have friends or family, or even yourselves, that have had to seek fertility treatment, you may know a little bit about what's involved in that. The company started off as a medical device company. We developed a technology that we refer to as INVOcell. This device is used to provide an alternative treatment method to what is currently the standard in advanced fertility care, in vitro fertilization. The device was originally cleared by the FDA in late 2015. A few years later, we actually submitted a 510 on this device to expand its usage. That 510 was also cleared by the FDA in 2023. A few years after our early commercialization efforts with the device, we made a decision to expand the scope of the business in an effort to build a larger operation within the fertility industry, we expanded into the clinic services side of the business. Today, we have four fully operational fertility clinics in Wisconsin, Indiana, Georgia, and Alabama. Our focus is to continue to build this clinic network by way of acquisitions. Three of the clinics actually use our INVOcell device as a treatment option for patients, one of the clinics just continues to do conventional IVF. Before I get into talking a little bit more about the industry and our strategy, I thought it would make sense to talk a little bit about the investment case and why we think we're at an interesting point in the company's history. Like many small microcap companies, we've had our challenges in building the business. I think we've made a lot of progress over the last 18 months, especially in the last six or seven months. First, we believe our cap structure has been greatly simplified. We had a fairly complex convertible Series C-2 preferred that has now been completely converted or retired. We eliminated some warrant liabilities. We did conduct a financing in January of this year at a fixed price of $795. The warrants associated with that financing are also at $795. If you were to look, you'd see that's quite a bit above our current stock price today. We have 1.8 million shares in our primary outstanding. That financing at the beginning of this year, combined with the financing we did right at the end of last year, brought in a total of about $11.5 million in gross proceeds to the business, we greatly strengthened our balance sheet through those efforts. We completed a majority divestiture of NAYA Therapeutics. This was a unrelated business to our fertility operations, we removed the cost and the distraction of that business and went back to our core focus on the fertility business. We did recently conduct a reverse stock split to maintain NASDAQ bid compliance. Combined with the cap structure cleanup, along with this split, we think we've, again, greatly simplified our cap structure and a much more investor-friendly structure. As part of the NAYA Therapeutics divestiture, we also rebranded the company from our older name to INVO Fertility to better align with our more expanded scope in the business. We also obtained the new ticker symbol, IVF. Operationally speaking, we think we have refined our acquisition approach, and we expect that future acquisition will be quite additive to the business. We are also implementing organic growth strategies within our existing clinics, and we're starting to see some of the benefits of those efforts. We also, last year, were able to receive a new patent on our INVOcell device that extended the protection on the device through 2040. Our Wisconsin clinic, which is our largest clinic, also recently was able to join the Progyny network. This expands the potential number of patients in the local area, patients that are covered under the Progyny insurance network. That's actually a fairly exciting development for our Wisconsin clinic. That just recently happened. Equally important, we've recently strengthened our operations team, bringing in people that have deep clinical operations experience to prepare us for the next phase of our growth. A little bit about the market. As a specialty healthcare area, the fertility market is fairly sizable. It's about $6 billion here in the U.S. It has seen fairly steady growth, and forecasts are for that to continue. There's a number of demand drivers that have helped contribute to that consistent growth. We continue to see a high incidence rate of infertility in the population. As some of you may know, the affordability or cost has been a significant prohibiting factor for a lot of patients in their ability to seek care. Historically, the cost of care has been an out-of-pocket expense for many patients, but this has been an area that has seen steady improvement in insurance coverage. We have an administration that is also pushing policy agenda to further this, and this all helps with affordability for patients. Making it more affordable, we believe, is a contributing major factor to this, again, steady demand pressure in the marketplace. The clinic landscape in the U.S. is made up of about 460 fertility clinics. That clinic network is doing over 400,000 treatment cycles here in the U.S., and, again, has seen steady growth. There has been fairly substantial investor interest in the space. We estimate approximately 60% of this clinic landscape has been consolidated under larger network groups. That investor interest has largely come from private equity. Despite this consolidation that's happened, it's still a fairly fragmented market with a lot of individual owner-operated clinics, and that's important for our focus. As I mentioned, we are very focused in the near term on our acquisition strategy. We believe this provides a faster pathway to build a more scalable business. As a small company, we believe we have a fairly robust pipeline of potential deal flow. We have active discussions going on with multiple opportunities. We think our public platform does provide some benefits or differences than the private equity route. In addition to this near-term focus on clinics, because of our technology heritage and our INVOcell device itself, we are also always looking for other innovative technologies that we can bring into our clinics that can help with making the operation more efficient or helping with patient experiences. This is another area of activity that we're evaluating always. We also recognize that there is only a finite number of potential clinics we could acquire. Longer term in our thinking is that to continue growing, we would build new clinics from the ground up. The good news is we've done both of these activities. Our first two clinics, we actually built from scratch in collaboration with physician partners. That was in Atlanta, Georgia, and Birmingham, Alabama. The other two clinics we've acquired. We've both bought and built now. I would say that our team, we have learned a lot. We think the steepest part of the learning curve is on your first transactions. Doesn't mean we don't have more to learn still, but this is where we've refined our approach and how we want to continue to conduct transactions on a go-forward basis. We've added important team members that have been with larger operations that also have done this before. Just a little bit about Wisconsin. This was our first acquisition. This is our biggest clinic. This was a well-respected clinic in the area. Has a strong team in place. There is room for growth. Again, we've been implementing strategies to help grow the clinic. We've added additional services. The addition of the Progyny network is a big one. We're excited about the forward look with Wisconsin. From a deal structure standpoint, we acquired this clinic in an all-cash deal spread out over time. We are nearing completion on the final payoff on this clinic. That will be done this year. I would say that our go-forward deal structure will be a little different, probably more like what we did with the recent Indianapolis clinic. We just completed the acquisition of Indianapolis in February of this year. That structure was more of a combination of cash and equity. The seller took an equity component as part of the transaction. That's our preferred structures on a go-forward basis. All of our discussions currently happening with various sellers, that's resonating just fine with them. Our message to potential clinic acquisition operators is that we want to take a very collaborative and synergistic approach. What we generally see is most physicians would prefer to focus on providing great patient care and not have to deal with all the operational back-office accounting, marketing, et cetera. Of course, that's our objective, too, is we want to free physician operators from having to do those things and utilize our operations team to manage all those activities for them. There's alignment in how best to operate the clinics on a go-forward basis. Again, as a public company taking equity, there's shared alignment in seeing future success in the business. On the technology side, again, as I mentioned, aside from our INVOcell device, we are also looking more broadly at other technologies that we might be able to bring into the clinic. Our INVOcell device, as I mentioned, serves as an alternative treatment method. It's essentially utilizing our device and the patient's own body to substitute for the sophisticated lab incubator. There's a lot of additional information we could talk about how that device works. I'm not sure we have the time. On our website, there's a lot of good information about how it works. Most importantly, on the device is we have demonstrated that it has comparable outcomes or success rates to conventional IVF. This is real-world market data that we were able to pull from clinics that had been outside of us, had been longtime users of our technology. This is real patient data, and that was actually the data that we used to support our 510 submission for the expanded usage that was cleared by the FDA. On financials, we have clearly benefited from our entry into the clinic services side of the business. We've seen good growth in the revenue. We completed 2025 at $6.8 million in revenue. We told the market at the beginning of this year that with the combination of the Indianapolis acquisition, we believe that our go-forward gross annualized revenue run rate on our clinic, our existing clinic network, is closer to $9 million today. We've also been making progress on our EBITDA. We did see some worsening of that in 2025. That was a direct result of our adding to our team and putting some additional infrastructure and pieces in place in anticipation of the growth that we're planning for for this year and beyond. We do believe that we will resume seeing EBITDA progress and leverage those investments that we've recently made as we get into the latter part of this year. On the balance sheet, 2025 is showing there. I would note that we were delayed in filing our 10. You may have already seen that. Due to some of the very complex transactions that we had conducted last year related to the preferred I mentioned, the warrant liabilities, the divesture of the NAYA Therapeutics asset, our new auditors that we engaged for this year needed to take additional time to really review those complex transactions. Had nothing to do with our core fertility operations. It did delay us in getting our 10 filed. It has been filed now. That delay also backed up filing our 10, our first quarter. That's why the first quarter's not being reflected on here on the balance sheet. We do expect that first quarter to be filed very soon. The point being called out here is that the cash balances reported year-end obviously did not reflect the additional financing that occurred in January of an additional $ 7.5 Million. A little more details on the cap table. Based on today's stock price, we're trading about a $2.6 million market cap. As I mentioned, we have 1.8 million shares outstanding. If you consider all the warrants, we have a small convertible debt at a fixed price as well as the acquisition of Indianapolis. The seller took equity in a preferred that's also at a fixed conversion price. If you've assumed converting all that, we'd have a fully diluted of 4.85 million shares. That would also bring in another $15 million in cash. Just to quickly summarize, we think we have an excellent foundation with our four existing clinics that we expect to build upon. We're very focused on our acquisition activity. Again, a very strong pipeline relative our size. We think any acquisition's going to be quite additive to the business from here. We are going to continue to look to integrate technologies where it makes sense within this clinic network, including our INVOcell device. The industry has very favorable tailwinds that's benefiting everybody, including ourselves. We would expect that to continue. We believe we're making excellent progress, again, at achieving one of our primary near-term objectives of bringing the business to a cash flow positive state and then continue to grow from there. Appreciate your time. Thank you very much. I'm not sure if we have time for questions, but Great. Did we get done early? Thanks. Thank you everyone. Appreciate it. Thank you